Doxazosin tablets recalled due to manufacturing quality control deviations
Accord Healthcare is recalling 75,190 bottles of Doxazosin 4 mg tablets due to manufacturing quality control deviations discovered during an FDA inspection. No illnesses have been reported.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall with no reported illnesses or injuries. The manufacturing quality control deviations identified during FDA inspection represent a potential risk of harm where injury has not yet been reported.
Plain-English summary
Accord Healthcare, Inc. is recalling Doxazosin tablets USP, 4 mg, due to manufacturing quality control deviations identified during a U.S. Food and Drug Administration inspection.
The recall affects 75,190 bottles distributed in the United States, including Puerto Rico and Canada. Affected batches are: R2200352 (expires 5/31/2024), R2200356 (expires 8/31/2024), R2200357 (expires 8/31/2024), R2200633 (expires 4/30/2025), R2200634 (expires 4/30/2025), R2200677 (expires 8/31/2024), R2200572 (expires 4/30/2025), R2200571 (expires 4/30/2025), and R2200646 (expires 4/30/2025). The affected product is sold under NDC numbers 16729-213-01 (100-count bottles) and 16729-213-17 (1,000-count bottles).
Patients currently taking this medication should not stop their medication without consulting their healthcare provider or pharmacist. No illnesses or adverse events associated with this recall have been reported.
The recalled product
- Product
- DOXAZOSIN (DOXAZOSIN)
- Brand
- DOXAZOSIN
- Manufacturer
- Accord Healthcare, Inc.
- Category
- Drug
- Hazard
- Affected units
- 75,190
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (12)
- Batches: a) R2200352
- Exp. Date 5/31/2024
- R2200356
- Exp. Date 8/31/2024
- R2200357
- R2200633
- Exp. Date 4/30/2025
- R2200634
- b) R2200677
- R2200572
- R2200571
- R2200646
UPCs (2)
- 316729213011
- 316729213172
Distribution
Distributed in 1 state:
Part of a larger recall action
This product is one of 67 recalled by Accord Healthcare, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 67 products in this recall →Related recalls
Same brand · DOXAZOSIN
- HighPrescription drug recall for manufacturing quality control deviations
FDA (Drugs) · 2023-05-03
- ModeratePrescription Doxazosin Tablets Recalled Due to Manufacturing Practice Deviations
FDA (Drugs) · 2023-03-08
- ModerateAccord Healthcare Doxazosin Tablets Recalled for Manufacturing Deviations
FDA (Drugs) · 2023-03-08
- ModeratePrescription Doxazosin Tablets Recalled for Manufacturing Deviations
FDA (Drugs) · 2023-03-08
Same manufacturer · Accord Healthcare, Inc.
See all →- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateSildenafil Citrate USP Recalled for CGMP Deviations Noted During FDA Inspection
FDA (Drugs) · 2026-08-19
- ModerateSildenafil Citrate Recall Due to CGMP Deviations
FDA (Drugs) · 2026-08-19